Qlife Holding AB: Business Update for First Half of 2026

Qlife Holding AB has issued a business update covering the first half of 2026. During this period, the company has continued to advance multiple strategic partnership initiatives within both the pharmaceutical and diagnostics sectors.

Concurrently, Qlife has maintained steady progress on its Egoo Health platform and regulatory milestones. An ongoing feasibility project with a global pharmaceutical company is progressing as planned, with expectations of a next-stage agreement following the completion of current activities.

Furthermore, Qlife is engaged in discussions with a pharmaceutical company for the development of a novel Egoo diagnostic solution. While the company has not provided specific details on future steps or timelines, it highlights the importance of partnerships for its platform's market entry.

Qlife is currently focusing on strengthening strategic alliances and navigating regulatory processes to bring its diagnostic platform to market. The company's announcement did not include financial figures or specific details regarding the value of these partnerships.